Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 25, 2013
Grant Date -
May 17, 2012
app pub date -
Dec 2, 2009
filing date -
Dec 2, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability, the p53 recombinant protein is effectively transduced into cells so that the tumor suppressor p53 can be translocated into cell nuclei. Within nuclei, p53 inhibits the formation of cyclin-CDK complexes to halt the cell cycle, thus suppressing excessive cell proliferation and inducing apoptosis of tumor cells. Therefore, the p53 recombinant protein can be useful as an anticancer agent in the treatment of various cancers.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully